Rise and shine, everyone, another busy day is on the way. Although not so busy for our shortest person, who is sleeping in thanks to a seasonal malady. Distractions aside, we are quaffing cups of stimulation and foraging for interesting items. Speaking of which, here is the latest crop. We hope your day goes well and would like to remind federal workers that we accept leaks — of any kind — and respect confidentiality. Have a smashing day, folks …
Johnson & Johnson agreed to buy Actelion Pharmaceuticals for $30 billion, bolstering its portfolio of rare disease treatments as its top-selling drug, Remicade, faces new competition, the Wall Street Journal writes. As part of the deal, Actelion will spin off its drug discovery operations into a separate company called R&D NewCo, and J&J will initially hold 16 percent of the shares of the venture, with an option to buy another 16 percent.
About the Author Reprints
